![Activity of the EGFR-HER2 Dual Inhibitor Afatinib in EGFR-Mutant Lung Cancer Patients With Acquired Resistance to Reversible EGFR Tyrosine Kinase Inhibitors]()
Activity of the EGFR-HER2 Dual Inhibitor Afatinib in EGFR-Mutant Lung Cancer Patients With Acquired Resistance to Reversible EGFR Tyrosine Kinase InhibitorsLandi, Lorenza; Tiseo, Marcello; Chiari, Rita; Ricciardi, Serena; Rossi, Elisa; Galetta, Domenico; Novello, Silvia; Milella, Michele; D'Incecco, Armida; Minuti, Gabriele; Tibaldi, Carmelo; Salvini, Jessica; Facchinetti, Francesco; Haspinger, Eva Regina; Cortinovis, Diego; Santo, Antonio; Banna, Giuseppe; Catino, Annamaria; GiajLevra, Matteo; Crinò, Lucio; de Marinis, Filippo; Cappuzzo, Federico · Clinical Lung Cancer · 2014